UPDATE: Amarin Spokesperson Tells Benzinga 'Vascepa's new FDA-approved cardiovascular risk reduction indication has received a significant amount of attention,' Says Co. Sees Patient Access Improving Overall As Payers Adapt New Indication
Benzinga Newsdesk